Skip to Content

'
David J. Stewart, M.D.

Present Title & Affiliation

Primary Appointment

Professor, Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, University of Texas M D Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1974 Queen's University, Kingston, Canada, MD, Medicine

Postgraduate Training

1976-1978 Fellow, Oncology, UT MD Anderson Cancer Center, Developmental Therapeutics, Houston, TX
1975-1976 Residency, Internal Medicine, Royal Victoria Hospital, Montreal, PQ, Canada
1974-1975 Internship, Internal Medicine, Royal Victoria Hospital, Montreal, PQ, Canada

Selected Publications

Peer-Reviewed Original Research Articles
1. Heymach JV, Paz-Arez L, De Braud F, Sebastian M, Stewart DJ, Eberhardt WE, Ranade AA, Cohen G, Trigo JM, Sandler AB, Bonomi PD, Herbst RS, Krebs Ad, Vasselli J, Johnson BE. Randomized phase II study of Vandetanib alone or with Paclitaxel and Carboplatin as first-line treatment for advanced non-samll cell luing cancer. J Clin Oncol 20(33):5407-15, 11/2009. PMID: 18936474.
2. Burger JA, Stewart DJ. CXCR4 chemokine receptor antagonists: Perspectives in SCLC. Expert OPin Investig Drugs 18(4):481-90, 4/2009. PMID: 19335276.
3. Stewart DJ, Kurzrock R. Cancer: The Road to Amiens. J Clin Oncol 27(3):328-33, 1/2009. PMID: 19064964.
4. Srivastata G, Rana V, Wallace S, Taylor S, Debnam M, Feng L, Suki D, Karp D, Stewart D, Oh Y. Risk of intracranial hemorrhage and cerebrovascular incidents in non-lung cancer brain metastasis patients. J Thorac Oncol 4(3):333-7, 2009. PMID: 19190519.
5. Stewart DJ. Gefitinib maintenance in stage III non-small-cell lung cancer. J Clin Oncol 26(29). e-Pub 9/2008. PMCID: PMC18779595.
6. Xing J, Stewart DJ, Gu J, Lu C, Spitz MR, Wu X. Expression of methylation-related genes is associated with overall survival in patients with non-small cell lung cancer. Br J Cancer 98(10):1716-22, 2008.
7. Wu X, Lu C, Ye Y, Chang J, Yang H, Lin J, Gu J, Hong WK, Stewart DJ, Spitz MR. Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy. Pharmacogenetics and Genomics 18(11):955-65, 2008.
8. Oh Y, Stewart DJ. Systemic therapy for lung cancer brain metastases: a rationale for clinical trials. Oncology 22(2):168-78, 2008.
9. Marom EM, Martinez CH, Truong MT, Lei X, Sabloff BS, Munden RF, Gladish GW, Herbst RS, Morice RC, Stewart DJ, Jimenez CA, Blumenschein GR Jr, Onn A. Tumor cavitation during therapy with antiangiogenesis agents in patients with lung cancer. J Thorac Oncol 3(4):351-7, 2008.
10. William WN, Zinner RG, Karp DD, Oh YW, Glisson BS, Phan SC, Stewart DJ. Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung cancer. J Thorac Oncol 2(8):745-50, 8/2007. PMID: 17762342.
11. Yang H, Spitz MR, Stewart DJ, Lu C, Gorlov IP, Wu X. ATM sequence variants associate with susceptibility to non-small cell lung cancer. Int. J. Cancer 121 (10):2254-9, 2007.
12. Stewart DJ, Chiritescu G, Dahrouge S, Banerjee S, Tomiak EM. Chemotherapy dose-response relationships in non-small cell lung cancer and implied resistance mechanisms. Cancer Treatment Rev 33(2):101-37, 2007.
13. Xing J, Spitz MR, Lu C, Zhao H, Wang W, Stewart DJ, Wu X. Deficient G2-M and S checkpoints are associated with increased lung cancer risk: a case-control analysis. Cancer Epidem Biomarkers Prev 16 (7):1517-22, 2007.
14. Wang W, Spitz MR, Yang H, Lu C, Stewart DJ, Wu X. Genetic variants in cell cycle control pathway confer susceptibility to lung cancer. Clin Cancer Res 13:5974-81, 2007.
15. Altundag O, Stewart DJ, Fossella FV, Ayers Gd, Wei W, Zhou X, Zinner RG. Many patients 80 years and older with advanced non-small cell lung cancer (NSCLC) can tolerate chemotherapy. J Thorac Oncol 2(2):141-6, 2007.
16. Stewart DJ. Mechanisms of Resistance to Cisplatin and Carboplatin. Crit Rev Oncol/Hematol 63:12-31, 2007.
17. William Jr. WM, Zinner RG, Karp DD, Oh YW, Glisson BS, Phan S-C, Stewart DJ. Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for treatment of non-small cell lung cancer. J Thor Oncology 2(8):745-50, 2007.

Last updated: 9/15/2009